Hepatic Arterial Infusion Pump Chemotherapy for Colorectal Liver Metastases: Making a Comeback?

Madhu Subramanian, Michael A. Choti, Adam C. Yopp

Research output: Contribution to journalArticle

Abstract

Nearly half of patients diagnosed with colorectal cancer will develop metastases during their lifetime; the majority of them were found within the liver. Surgical resection of liver metastases is the only curative therapy with 5-year survival rates ranging from 40 to 58 %. Unfortunately, less than 25 % of patients are eligible for resection. Before the advent of the modern systemic chemotherapy era, the administration of hepatic artery infusion (HAI) chemotherapy was widespread in the treatment of colorectal liver metastasis (CLM). However, due to a lack of demonstrated increased survival following HAI therapy compared to systemic chemotherapy alone, its use has fallen out of favor. Recently, multiple studies have demonstrated that HAI therapy may fill a role in the treatment of CLM disease in patients who have either progressed on first-line systemic chemotherapy in the palliative setting or are considered candidates for conversion from unresectable to resectable liver-only disease. The lack of large randomized clinical trials demonstrating clinical efficacy has precluded HAI chemotherapy use to be considered standard of care outside of a research setting in the adjuvant setting.

Original languageEnglish (US)
Pages (from-to)231-240
Number of pages10
JournalCurrent Colorectal Cancer Reports
Volume11
Issue number5
DOIs
StatePublished - Jun 11 2015
Externally publishedYes

Fingerprint

Infusion Pumps
Hepatic Artery
Neoplasm Metastasis
Drug Therapy
Liver
Liver Diseases
Therapeutics
Standard of Care
Colorectal Neoplasms
Survival Rate
Randomized Controlled Trials
Survival
Research

Keywords

  • Colorectal carcinoma
  • Colorectal liver metastases
  • Hepatic artery chemotherapy
  • Systemic chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Hepatology

Cite this

Hepatic Arterial Infusion Pump Chemotherapy for Colorectal Liver Metastases : Making a Comeback? / Subramanian, Madhu; Choti, Michael A.; Yopp, Adam C.

In: Current Colorectal Cancer Reports, Vol. 11, No. 5, 11.06.2015, p. 231-240.

Research output: Contribution to journalArticle

Subramanian, Madhu ; Choti, Michael A. ; Yopp, Adam C. / Hepatic Arterial Infusion Pump Chemotherapy for Colorectal Liver Metastases : Making a Comeback?. In: Current Colorectal Cancer Reports. 2015 ; Vol. 11, No. 5. pp. 231-240.
@article{23226c539c34451986a7c247f883cb21,
title = "Hepatic Arterial Infusion Pump Chemotherapy for Colorectal Liver Metastases: Making a Comeback?",
abstract = "Nearly half of patients diagnosed with colorectal cancer will develop metastases during their lifetime; the majority of them were found within the liver. Surgical resection of liver metastases is the only curative therapy with 5-year survival rates ranging from 40 to 58 {\%}. Unfortunately, less than 25 {\%} of patients are eligible for resection. Before the advent of the modern systemic chemotherapy era, the administration of hepatic artery infusion (HAI) chemotherapy was widespread in the treatment of colorectal liver metastasis (CLM). However, due to a lack of demonstrated increased survival following HAI therapy compared to systemic chemotherapy alone, its use has fallen out of favor. Recently, multiple studies have demonstrated that HAI therapy may fill a role in the treatment of CLM disease in patients who have either progressed on first-line systemic chemotherapy in the palliative setting or are considered candidates for conversion from unresectable to resectable liver-only disease. The lack of large randomized clinical trials demonstrating clinical efficacy has precluded HAI chemotherapy use to be considered standard of care outside of a research setting in the adjuvant setting.",
keywords = "Colorectal carcinoma, Colorectal liver metastases, Hepatic artery chemotherapy, Systemic chemotherapy",
author = "Madhu Subramanian and Choti, {Michael A.} and Yopp, {Adam C.}",
year = "2015",
month = "6",
day = "11",
doi = "10.1007/s11888-015-0277-2",
language = "English (US)",
volume = "11",
pages = "231--240",
journal = "Current Colorectal Cancer Reports",
issn = "1556-3790",
publisher = "Springer Science + Business Media",
number = "5",

}

TY - JOUR

T1 - Hepatic Arterial Infusion Pump Chemotherapy for Colorectal Liver Metastases

T2 - Making a Comeback?

AU - Subramanian, Madhu

AU - Choti, Michael A.

AU - Yopp, Adam C.

PY - 2015/6/11

Y1 - 2015/6/11

N2 - Nearly half of patients diagnosed with colorectal cancer will develop metastases during their lifetime; the majority of them were found within the liver. Surgical resection of liver metastases is the only curative therapy with 5-year survival rates ranging from 40 to 58 %. Unfortunately, less than 25 % of patients are eligible for resection. Before the advent of the modern systemic chemotherapy era, the administration of hepatic artery infusion (HAI) chemotherapy was widespread in the treatment of colorectal liver metastasis (CLM). However, due to a lack of demonstrated increased survival following HAI therapy compared to systemic chemotherapy alone, its use has fallen out of favor. Recently, multiple studies have demonstrated that HAI therapy may fill a role in the treatment of CLM disease in patients who have either progressed on first-line systemic chemotherapy in the palliative setting or are considered candidates for conversion from unresectable to resectable liver-only disease. The lack of large randomized clinical trials demonstrating clinical efficacy has precluded HAI chemotherapy use to be considered standard of care outside of a research setting in the adjuvant setting.

AB - Nearly half of patients diagnosed with colorectal cancer will develop metastases during their lifetime; the majority of them were found within the liver. Surgical resection of liver metastases is the only curative therapy with 5-year survival rates ranging from 40 to 58 %. Unfortunately, less than 25 % of patients are eligible for resection. Before the advent of the modern systemic chemotherapy era, the administration of hepatic artery infusion (HAI) chemotherapy was widespread in the treatment of colorectal liver metastasis (CLM). However, due to a lack of demonstrated increased survival following HAI therapy compared to systemic chemotherapy alone, its use has fallen out of favor. Recently, multiple studies have demonstrated that HAI therapy may fill a role in the treatment of CLM disease in patients who have either progressed on first-line systemic chemotherapy in the palliative setting or are considered candidates for conversion from unresectable to resectable liver-only disease. The lack of large randomized clinical trials demonstrating clinical efficacy has precluded HAI chemotherapy use to be considered standard of care outside of a research setting in the adjuvant setting.

KW - Colorectal carcinoma

KW - Colorectal liver metastases

KW - Hepatic artery chemotherapy

KW - Systemic chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84940453340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940453340&partnerID=8YFLogxK

U2 - 10.1007/s11888-015-0277-2

DO - 10.1007/s11888-015-0277-2

M3 - Article

AN - SCOPUS:84940453340

VL - 11

SP - 231

EP - 240

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

SN - 1556-3790

IS - 5

ER -